BioCentury
ARTICLE | Clinical News

Galapagos slides on trial updates for GSK2586184

March 1, 2014 1:10 AM UTC

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) slid EUR 1.76 (10%) to EUR 16.50 on Friday after announcing that partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) stopped a Phase II trial evaluating GSK2586184 (formerly GLPG0778) to treat systemic lupus erythematosus (SLE). According to Galapagos, GSK stopped the trial after a planned interim analysis showed a "lack of effect" for the Janus kinase-1 (JAK-1) inhibitor. Galapagos said GSK also placed a Phase I/II trial evaluating GSK2586184 for ulcerative colitis (UC) on hold. Galapagos deferred questions to GSK, which was not able to respond in time for publication. ...